Firms Look To Clinical Guidelines To Boost Prostate Cryosurgery Market

Article preview from "The Gray Sheet" - June 9, 2008

Find out why device manufacturers are saying that new "best practice" statements citing cryosurgery as a treatment option for men with prostate cancer could help boost the use of the technology beyond its modest penetration rate.

New "best practice" statements citing cryosurgery as a treatment option for men with prostate cancer could help boost the use of the technology beyond its modest penetration rate, device manufacturers say.

The best practice committee chairman for the American Urological Association, Richard J. Babaian, M.D., presented formal statements endorsing the treatment strategy in some instances at the AUA annual meeting May 19 in Orlando.

Mary Syiek, vice president of clinical research for Endocare, the leading manufacturer of cryoprobes and other products used for prostate cryosurgery, said the AUA endorsement "provides a clinical legitimacy" to the technology, which has not received the response from physicians she thinks it deserves.

"A lot of people don't know about the technology," Syiek said in an interview. "We're trying to get the word out to as many clinicians as possible."

Purchase the full story online or get it free when register for your 30-day free trial of "The Gray Sheet"